| Malignant neoplasm of breast
Kisqali vs Ibrance
Side-by-side clinical, coverage, and cost comparison for malignant neoplasm of breast.Deep comparison between: Kisqali vs Ibrance with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsIbrance has a higher rate of injection site reactions vs Kisqali based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Ibrance but not Kisqali, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Kisqali
Ibrance
At A Glance
Oral
Once daily (21/28-day cycle)
CDK4/6 inhibitor
Oral
Once daily (21 of 28 days)
CDK4/6 inhibitor
Indications
- Malignant neoplasm of breast
- Advanced breast cancer
- Malignant neoplasm of breast
Dosing
Malignant neoplasm of breast 400 mg (two 200 mg tablets) orally once daily for 21 consecutive days followed by 7 days off in 28-day cycles, in combination with an aromatase inhibitor, for 3 years or until disease recurrence or unacceptable toxicity.
Advanced breast cancer 600 mg (three 200 mg tablets) orally once daily for 21 consecutive days followed by 7 days off in 28-day cycles, in combination with fulvestrant or an aromatase inhibitor.
Malignant neoplasm of breast 125 mg orally once daily for 21 consecutive days followed by 7 days off to comprise a 28-day cycle; taken with food. Dose may be reduced to 100 mg or 75 mg for adverse reactions; patients with severe hepatic impairment (Child-Pugh C) start at 75 mg once daily.
Contraindications
—
—
Adverse Reactions
Most common (>=20%) Neutrophils decreased, leukocytes decreased, lymphocytes decreased, hemoglobin decreased, ALT increased, AST increased, infections, nausea, fatigue, headache, creatinine increased, platelets decreased, diarrhea, vomiting, alopecia, cough, rash, back pain
Serious Interstitial lung disease/pneumonitis, severe cutaneous adverse reactions (SJS, TEN), QT interval prolongation, hepatotoxicity, neutropenia
Postmarketing Interstitial lung disease/pneumonitis, Stevens-Johnson syndrome, toxic epidermal necrolysis, drug-induced hypersensitivity syndrome/DRESS
Most common (>=10%) Neutropenia, infections, leukopenia, fatigue, nausea, alopecia, stomatitis, diarrhea, anemia, rash, asthenia, thrombocytopenia, vomiting, decreased appetite, dry skin, pyrexia, dysgeusia
Serious Neutropenia, leukopenia, infections, anemia
Postmarketing Interstitial lung disease (ILD)/non-infectious pneumonitis, palmar-plantar erythrodysesthesia syndrome (PPES)
Pharmacology
Ribociclib is a CDK4/6 inhibitor that blocks cyclin D-CDK4/6-mediated phosphorylation of the retinoblastoma protein (pRb), arresting the cell cycle in the G1 phase and reducing proliferation in breast cancer models; in combination with antiestrogen therapy (letrozole or fulvestrant), it produces greater tumor growth inhibition than either agent alone.
Palbociclib is an inhibitor of cyclin-dependent kinases (CDK) 4 and 6; it blocks progression of ER-positive breast cancer cells from G1 into S phase of the cell cycle, and in combination with antiestrogens decreases Rb protein phosphorylation, reduces E2F expression, and increases growth arrest.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Kisqali
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (12/12)
Ibrance
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (11/12)
UnitedHealthcare
Kisqali
- Covered on 4 commercial plans
- PA (8/8) · Step Therapy (0/8) · Qty limit (7/8)
Ibrance
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (2/8)
Humana
Kisqali
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Ibrance
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (2/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$25/momo
Novartis Oncology Universal Co-pay Program: KisqaliCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Breast Cancer
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
KisqaliView full Kisqali profile
IbranceView full Ibrance profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.